Absence of germline CHK2 mutations in familial gastric cancer

被引:18
作者
Kimura, K [1 ]
Shinmura, K
Yoshimura, K
Shimizu, K
Katai, H
Beppu, Y
Moriya, H
Yokota, J
机构
[1] Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Chuo Ku, Tokyo 1040045, Japan
[3] Natl Canc Ctr Hosp, Gastr Surg Div, Chuo Ku, Tokyo 1040045, Japan
[4] Natl Canc Ctr Hosp, Div Orthopaed Surg, Chuo Ku, Tokyo 1040045, Japan
[5] Chiba Univ, Dept Orthopaed Surg, Chuo Ku, Chiba 2608677, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 2000年 / 91卷 / 09期
关键词
CHK2; germline mutation; familial gastric cancer;
D O I
10.1111/j.1349-7006.2000.tb01028.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, the CHK2 gene was identified as being a candidate gene responsible for Li-Fraumeni syndrome (LFS), Gastric cancer is often clustered in families with LFS, so it is possible that germline CHK2 mutation is also present in familial gastric cancer (FGC), We therefore defined the genomic structure of the CHK2 gene, designed intronic primers, and searched for germline CHK2 mutations in 25 FGC Eases by polymerase chain reaction-single strand conformational polymorphism analysis of the entire coding region. In all of the 25 cases, at least two siblings had histories of gastric cancer. There were no FGC cases that showed germline CHK2 mutations, Thus, it was indicated that germline CHK2 mutations do not contribute to the familial clustering of gastric cancer.
引用
收藏
页码:875 / 879
页数:5
相关论文
共 36 条
[1]  
Aarnio M, 1997, INT J CANCER, V74, P551, DOI 10.1002/(SICI)1097-0215(19971021)74:5<551::AID-IJC13>3.0.CO
[2]  
2-9
[3]   Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome [J].
Bell, DW ;
Varley, JM ;
Szydlo, TE ;
Kang, DH ;
Wahrer, DCR ;
Shannon, KE ;
Lubratovich, M ;
Verselis, SJ ;
Isselbacher, KJ ;
Fraumeni, JF ;
Birch, JM ;
Li, FP ;
Garber, JE ;
Haber, DA .
SCIENCE, 1999, 286 (5449) :2528-2531
[4]   Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome [J].
Birch, JM ;
Blair, V ;
Kelsey, AM ;
Evans, DG ;
Harris, M ;
Tricker, KJ ;
Varley, JM .
ONCOGENE, 1998, 17 (09) :1061-1068
[5]  
Caldas C, 1999, J MED GENET, V36, P873
[6]   Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway [J].
Chaturvedi, P ;
Eng, WK ;
Zhu, Y ;
Mattern, MR ;
Mishra, R ;
Hurle, MR ;
Zhang, XL ;
Annan, RS ;
Lu, Q ;
Faucette, LF ;
Scott, GF ;
Li, XT ;
Carr, SA ;
Johnson, RK ;
Winkler, JD ;
Zhou, BBS .
ONCOGENE, 1999, 18 (28) :4047-4054
[7]  
Chehab NH, 2000, GENE DEV, V14, P278
[8]  
CRISTOFARO G, 1987, CANCER, V60, P51, DOI 10.1002/1097-0142(19870701)60:1<51::AID-CNCR2820600110>3.0.CO
[9]  
2-V
[10]  
Eng C, 1997, CANCER EPIDEM BIOMAR, V6, P379